iCAD Announces Board of Directors Transition
Dana Brown named Executive Chair of the BoardNASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical...
Cancer
Genetic Technologies Provides Business Update
MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based...
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market...
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial SolutionsMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health®...
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at...
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
REYKJAVIK, Iceland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for...
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
PRESS RELEASEREGULATED INFORMATION11 January 2023, 07:00 am CEST Ghent, Belgium – 11 January 2023 – Sequana Medical NV (Euronext Brussels:...
BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment
BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell...
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life...
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer...
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics
Proprietary AMPS platform enables the systematic and rapid interrogation of protein-metabolite interactions to reveal new, disease-relevant allosteric binding sitesCAMBRIDGE, Mass.,...
Helsinn closes financing agreement with Oberland Capital
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare...
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine
Eflornithine method for use patent from Michigan State University/Corewell Health® relates to treating patients with rare Bachmann-Bupp SyndromePALO ALTO, Calif.,...
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by...
Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A and Licensing Deals in 2023
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of InertiaMORRISVILLE, N.C., Jan....